SCHEMBL4336252

SCHEMBL4336252

CCn1ncc2c(NC3CCCCC3)c(C(=O)NCCc3ccc(OC)cc3)cnc21

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.61
PDE4D Q08499 12/20 0.59
CTSL P07711 1/20 0.57
CTSS P25774 1/20 0.57
CTSK P43235 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336974 0.92 PDE4B (0.69) PDE4BPDE4D
SCHEMBL4475060 0.92 PDE4B (0.68) PDE4BPDE4D
SCHEMBL4337128 0.92 PDE4B (0.68) PDE4BPDE4D
SCHEMBL4335704 0.91 PDE4B (0.64) PDE4BPDE4D
SCHEMBL4500416 0.91 PDE4B (0.64) PDE4BPDE4D
SCHEMBL4342549 0.90 PDE4B (0.63) PDE4BPDE4D
SCHEMBL4348767 0.90 PDE4B (0.70) PDE4BPDE4D
SCHEMBL4337611 0.89 PDE4B (0.69) PDE4BPDE4D
SCHEMBL7955464 0.89 L3MBTL1 (0.49) PDE4BPDE4DCTSLCTSSCTSK
SCHEMBL7955469 0.89 L3MBTL1 (0.49) PDE4BPDE4DCTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080175914-A1 Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED 2008-07-24 US claimed
US-20060089375-A1 Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2006-04-27 US claimed
EP-1539753-B1 PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LTD (GB) 2009-09-09 EP disclosed
US-20080175914-A1 Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED 2008-07-24 US disclosed
US-20060089375-A1 Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080175914-A1 Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors PDE5A, PDE3B, PDE4A PDE4B 4/4885PDE4D 22/4885CTSL 2831/4885
US-20060089375-A1 Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors PDE5A, PDE3B, PDE4A PDE4B 4/4885PDE4D 22/4885CTSL 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.